Prakt. Lékáren. 2017; 13(1e) [Klin Farmakol Farm. 2016;30(3):23-28]

New antibiotics in the clinical practise and in the clinical trials

Lenka Součková^{1, 2, 4, 5}, Adriana Ruzsíková^{2, 3}

¹ Masarykova Univerzita, Lékařská fakulta, Farmakologický ústav

² Fakultní nemocnice u sv. Anny v Brně, ICRC

³ Masarykova Univerzita, Lékařská fakulta, Anesteziologicko-resuscitační klinika

⁴ Fakultní nemocnice Brno, Klinika dětské onkologie

⁵ Masarykův onkologický ústav

Expanding of resistance of still susceptible strains of bacteria to antibiotics, associated with the increasing consumption of antibiotics in bothhuman and veterinary medicine, is occurring faster than the marketing approvals and the implementation of new antibiotic molecules to clinicalpractice. The development of new antibiotic molecules is troublesome, expensive and timeconsuming. Inspite of this, 30 new antibioticmolecules were registered in the last 15 years and more than 10 molecules are in the process of phase III clinical trials. Therefore we can expect further new marketing approvals in the field of antimicrobial drugs in the upcoming years. The article briefly describes the new antibioticsapproved since 2000. This review also summarizes the current status of clinical research in the field of antibiotics.

Keywords: new antibiotics, research and development of drugs, marketing approval, resistance

Published: April 1, 2017  Show citation